<DOC>
	<DOCNO>NCT01008852</DOCNO>
	<brief_summary>This study design evaluate safety efficacy dose dosage regimen SBI-087 seropositive patient active Rheumatoid Arthritis , stable dose methotrexate .</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Meets American College Rheumatology ( ACR ) 1987 revise criterion classification Rheumatoid Arthritis ( RA ) least 6 month prior screen Active RA define &gt; = 5 swollen &gt; = 5 tender joint ( 28joint count ) least 1 follow : Creactive protein &gt; = 10 mg/L Erythrocyte Sedimentation Rate &gt; = 28 mm/h Must seropositive define documented history rheumatoid factor ( RF ) anticyclic citrullinated peptide ( antiCCP ) positivity Must receive stable route dose methotrexate ( 25 mg weekly ) Any significant health problem rheumatoid arthritis Any clinically significant laboratory abnormality Any prior use B celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>seropositive</keyword>
	<keyword>methotrexate</keyword>
</DOC>